Familial Hypercholesterolemia Treatment Market Size & Report 2023-2030

Familial Hypercholesterolemia Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Familial Hypercholesterolemia Treatment Market is Segmented By Drug Type&nbsp;(Statins, Combination cholesterol absorption inhibitor and statin, Ezetimibe (Zetia), PCSK9 inhibitors, Fibrates, Omega-3 fatty acid supplements, Others), By Indication Type&nbsp;(Heterozygous familial hypercholesterolemia, Homozygous familial hypercholesterolemia), By Distribution Channel&nbsp;(Hospital Pharmacies, Retail Pharmacies, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

<h2>&nbsp;</h2>

<blockquote>
The Familial Hypercholesterolemia Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a high CAGR during the forecast period (2023-2030).
</blockquote>

Familial hypercholesterolemia is a genetic disease that runs in families. It raises LDL (bad) cholesterol levels dramatically. The disease starts at birth and can lead to heart attacks at a young age.

<h3>Familial Hypercholesterolemia Treatment Market Scope</h3>

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			High
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Drug Type,&nbsp;By Indication Type,&nbsp;By Distribution Channel, and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

<h3>Market Dynamics</h3>

The factors influencing the familial hypercholesterolemia treatment market are the increasing FDA approvals and demand for familial hypercholesterolemia treatment and the growing prevalence of familial hypercholesterolemia.

The increasing FDA approvals and demand for familial hypercholesterolemia treatment are expected to drive the market growth 

Familial hypercholesterolemia is a genetic disease that runs in families. It raises LDL (bad) cholesterol levels dramatically. The disease starts at birth and can lead to heart attacks at a young age. LDL cholesterol levels of over 190 mg/dL in adults (and over 160 mg/dL in children) are among the most common signs of FH. Furthermore, most FH people have a family history of early heart disease or heart attacks. Routine <a href="https://www.datamintelligence.com/research-report/blood-and-blood-products-market">blood</a> cholesterol screening can reveal elevated LDL levels in some cases.

The use of novel therapies as an adjunctive treatment for HoFH has been approved. Lomitapide, a microsomal triglyceride transfer protein inhibitor, can lower LDL-C by up to 46 percent in people over 18. In addition, injectable mipomersen, an antisense RNA therapy, is approved in the United States for children as young as 12 years old and can lower LDL-C by up to 25%. Monoclonal antibodies to PCSK9 are being touted as a new treatment option for FH. Moreover, the increasing FDA approvals are expected to drive market growth. For instance, on April 1st, 2021, Praluent (alirocumab) injection was approved by the Food and Drug Administration (FDA) for adult patients with homozygous familial hypercholesterolemia (HoFH). This genetic condition causes severely high cholesterol. Praluent isn&#39;t meant to be used on its own; it&#39;s meant to be combined with other HoFH treatments.

Limitations associated with familial hypercholesterolemia disease are expected to hamper the market growth

FH is frequently misdiagnosed and mistreated, especially in children. 10 Primary care providers bear the burden of early FH diagnosis. They have a unique opportunity to improve FH detection and management. 11 The National Heart, Lung, and Blood Institute, American Academy of Pediatrics, American Heart Association, National Lipid Association, and American College of Cardiology all recommend universal lipid screening in children aged 9 to 11 years, which has the potential to significantly improve case finding. Moreover, there are currently no long-term studies in children with FH that show a reduction in vascular events when LDL-C lowering treatment is started early. According to the study, children with FH have significantly greater carotid intimamedia thickness than their unaffected siblings, which can be detected as early as 8 to 10 years old.

<h3>COVID-19 Impact Analysis</h3>

Patients with familial hypercholesterolemia (FH) are more likely to develop COVID-19 complications during the infection&#39;s acute phase and for a long time afterward. Because the level of low-density lipoprotein cholesterol (LDL-C) in FH patients is elevated from birth and correlates with the degree of systemic endothelial dysfunction, both heterozygous FH (HeFH) and, in particular, homozygous FH (HoFH) patients have a dysfunctional endothelium that is vulnerable to further damage from the direct viral attack and the hyper-inflammatory response typical of severe COVID-19. The use of statins in patients with COVID-19 has been beneficial in the past. Therefore, the focus on FH patients should be on lowering LDL-C levels effectively, as this is the root cause of the expected increased vulnerability to COVID-19 infection. During the COVID pandemic, continued use of statins and other lipid-lowering therapies should be encouraged to reduce the risk of COVID-19-related cardiovascular complications. Hence, the covid-19 is expected to positively impact the market growth.

<h3>Segment Analysis</h3>

Based on drugs, the statins segment is expected to drive the market growth in the forecast period

Statins are microorganism-derived drugs that significantly reduce cholesterol synthesis in cells by inhibiting the enzyme HMG-CoA reductase&#39;s activity. Statins, on the other hand, lower cholesterol levels in the blood by increasing the number of high-affinity receptors that recognize plasma LDL and decreasing the rate of VLDL synthesis in the liver. This explains why these drugs have a minor triglyceride-lowering effect. The efficacy of statins in lowering plasma cholesterol levels is comparable to that of bile acid-binding polymers, but it is superior to that of fibrates and nicotinic acid. Statins have a better tolerability profile than the other two drugs, but they are less effective at lowering plasma triglycerides and increasing HDL cholesterol levels. At their maximum approved doses, the strongest statins, rosuvastatin, and atorvastatin, can reduce LDLc levels by 50-60%. Moreover, the FDA approvals of this drug are expected to boost its market growth. For instance, on 22nd December 2021, the FDA approved Leqvio (inclisiran) injection for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional low-density lipoprotein lowering in addition to diet and maximally tolerated statin therapy.

<h3>Geographical Analysis</h3>

North America region is expected to hold the largest market share in the global familial hypercholesterolemia treatment market

The growing prevalence of familial hypercholesterolemia and increasing FDA approvals in this region is expected to drive the market growth.

The prevalence of probable/definite FH in the United States was estimated at 0.40 percent (95 percent confidence interval [CI], 0.32-0.48), or 1 in 250 people (95 percent CI, 1 in 311 to 209). This means that 834,500 adults in the United States have FH. According to studies, the prevalence of heterozygous FH in the general population in the United States and worldwide is 1 in 250.

Moreover, on 23rd December 2021, The US Food and Drug Administration (FDA) approved Inclisiran (Leqvio) for lowering LDL-C in patients with atherosclerotic cardiovascular disease or heterozygous hypercholesterolemia.

<h3>Competitive Landscape</h3>

The global Familial Hypercholesterolemia Treatment Market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Amryt Pharmaceuticals, Inc., Novartis AG, AstraZeneca Plc., Regeneron Pharmaceuticals, Sanofi S.A., Amgen Inc., Daiichi Sankyo Company Limited, Esperion Therapeutics, Viatris Inc., Kowa Pharmaceuticals America, Inc. and Merck &amp; Co., Inc.

Novartis AG

Overview: Novartis International AG, based in Basel, Switzerland, is a multinational pharmaceutical corporation. It is one of the world&#39;s largest pharmaceutical corporations. The company was founded in 1996.

Product Portfolio: LEQVIO (inclisiran) is an injectable prescription medicine used in adults who need <a href="https://www.medicalnewstoday.com/articles/drugs-leqvio">additional</a> lowering of &quot;bad&quot; cholesterol (LDL-C) and have&nbsp; heterozygous familial hypercholesterolemia (HeFH).

Key Development: On 23rd December 2021, The US Food and Drug Administration (FDA) approved Novarti&rsquo;s Inclisiran (Leqvio) to lower LDL-C in patients with atherosclerotic cardiovascular disease heterozygous hypercholesterolemia.

<ol>
	<li>Methodology and Scope
	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Market Definition and Overview</li>
	<li>Executive Summary
	<ol>
		<li>Market Snippet By Drug Type</li>
		<li>Market Snippet By Indication Type</li>
		<li>Market Snippet By Distribution Channel</li>
		<li>Market Snippet By Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers:
			<ol>
				<li>The increasing FDA approvals and demand for familial hypercholesterolemia treatment</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Limitations associated with familial hypercholesterolemia disease</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis 
	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>By Drug Type
	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
		<li>Market Attractiveness Index, By Drug Type
		<ol>
			<li>Statins
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
				<ol>
					<li>Atorvastatin (Lipitor)</li>
					<li>Fluvastatin (Lescol XL)</li>
					<li>Lovastatin (Altoprev)</li>
					<li>Pitavastatin (Livalo, Zypitamag)</li>
					<li>Pravastatin (Pravachol)</li>
					<li>Rosuvastatin (Crestor, Ezallor)</li>
					<li>Simvastatin (Zocor)</li>
				</ol>
				</li>
			</ol>
			</li>
			<li>Combination cholesterol absorption inhibitor and statin</li>
			<li>Ezetimibe (Zetia)</li>
			<li>PCSK9 inhibitors</li>
			<li>Fibrates</li>
			<li>Omega-3 fatty acid supplements</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>By Indication Type
	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type</li>
		<li>Market Attractiveness Index, By Indication Type
		<ol>
			<li>Heterozygous familial hypercholesterolemia
			<ol>
				<li>
				<ol>
					<li>Introduction</li>
					<li>Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
				</ol>
				</li>
			</ol>
			</li>
			<li>Homozygous familial hypercholesterolemia</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacies
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>&nbsp;Other</li>
	</ol>
	</li>
	<li>By Region
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>&nbsp;Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>&nbsp;Novartis AG*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Amryt Pharmaceuticals, Inc.</li>
		<li>AstraZeneca Plc</li>
		<li>Regeneron Pharmaceuticals</li>
		<li>Amgen Inc</li>
		<li>Daiichi Sankyo Company Limited</li>
		<li>Esperion Therapeutics</li>
		<li>Viatris Inc.</li>
		<li>Kowa Pharmaceuticals America, Inc.</li>
		<li>Merck &amp; Co., Inc.(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>DataM&nbsp; Intelligence
	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>&nbsp;&nbsp;Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 01 Global Familial Hypercholesterolemia Treatment Market Value, By Drug Type, 2022, 2026 &amp; 2030 ($ Million)

Table 02 Global Familial Hypercholesterolemia Treatment Market Value, By Indication Type, 2022, 2026 &amp; 2030 ($ Million)

Table 03 &nbsp; Global Familial Hypercholesterolemia Treatment Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 ($ Million)

Table 04 Global Familial Hypercholesterolemia Treatment Market Value, By Region, 2022, 2026 &amp; 2030 ($ Million)

Table 05 Global Familial Hypercholesterolemia Treatment Market Value, By Drug Type, 2022, 2026 &amp; 2030 ($ Million)

Table 06&nbsp; Global Familial Hypercholesterolemia Treatment Market Value, By Drug Type, 2022, 2026 &amp; 2030 ($ Million)

Table 07 Global Familial Hypercholesterolemia Treatment Market Value, By Indication Type, 2022, 2026 &amp; 2030 ($ Million)

Table 08&nbsp; Global Familial Hypercholesterolemia Treatment Market Value, By Indication Type, 2022-2030($ Million)

Table 09&nbsp; Global Familial Hypercholesterolemia Treatment Market Value, By Distribution Channel, 2022, 2026 &amp; 2030 ($ Million)

Table 10&nbsp; Global Familial Hypercholesterolemia Treatment Market Value, By Distribution Channel, 2022-2030($ Million)

Table 11 Global Familial Hypercholesterolemia Treatment Market Value, By Region, 2022, 2026 &amp; 2030 ($ Million)

Table 12 Global Familial Hypercholesterolemia Treatment Market Value, By Region, 2022-2030($ Million)

Table 13 North America Familial Hypercholesterolemia Treatment Market Value, By Drug Type, 2022-2030($ Million)

Table 14 North America Familial Hypercholesterolemia Treatment Market Value, By Indication Type, 2022-2030($ Million)

Table 15 North America Familial Hypercholesterolemia Treatment Market Value, By Distribution Channel, 2022-2030($ Million)

Table 16 North America Familial Hypercholesterolemia Treatment Market Value, By Country, 2022-2030($ Million)

Table 17 South America Familial Hypercholesterolemia Treatment Market Value, By Drug Type, 2022-2030($ Million)

Table 18 South America Familial Hypercholesterolemia Treatment Market Value, By Indication Type, 2022-2030($ Million)

Table 19 South America Familial Hypercholesterolemia Treatment Market Value, By Distribution Channel, 2022-2030($ Million)

Table 20 South America Familial Hypercholesterolemia Treatment Market Value, By Country, 2022-2030($ Million)

Table 21 Europe Familial Hypercholesterolemia Treatment Market Value, By Drug Type, 2022-2030($ Million)

Table 22 Europe Familial Hypercholesterolemia Treatment Market Value, By Indication Type, 2022-2030($ Million)

Table 23 Europe Familial Hypercholesterolemia Treatment Market Value, By Distribution Channel, 2022-2030($ Million)

Table 24 Europe Familial Hypercholesterolemia Treatment Market Value, By Country, 2022-2030($ Million)

Table 25 Asia-Pacific Familial Hypercholesterolemia Treatment Market Value, By Drug Type, 2022-2030($ Million)

Table 26 Asia-Pacific Familial Hypercholesterolemia Treatment Market Value, By Indication Type, 2022-2030($ Million)

Table 27 Asia-Pacific Familial Hypercholesterolemia Treatment Market Value, By Distribution Channel, 2022-2030($ Million)

Table 28 Asia-Pacific Familial Hypercholesterolemia Treatment Market Value, By Country, 2022-2030($ Million)

Table 29 Middle East &amp; Africa Familial Hypercholesterolemia Treatment Market Value, By Drug Type, 2022-2030($ Million)

Table 30 Middle East &amp; Africa Familial Hypercholesterolemia Treatment Market Value, By Indication Type, 2022-2030($ Million)

Table 31 Middle East &amp; Africa Familial Hypercholesterolemia Treatment Market Value, By Distribution Channel, 2022-2030($ Million)

Table 32 Novartis AG: Overview

Table 33 Novartis AG: Product Portfolio

Table 34 Novartis AG: Key Developments

Table 35 Amryt Pharmaceuticals, Inc.: Overview

Table 36 Amryt Pharmaceuticals, Inc.: Product Portfolio

Table 37 Amryt Pharmaceuticals, Inc.: Key Developments

Table 38 AstraZeneca Plc: Overview

Table 39 AstraZeneca Plc: Product Portfolio

Table 40&nbsp; AstraZeneca Plc: Key Developments

Table 41 Regeneron Pharmaceuticals: Overview

Table 42 Regeneron Pharmaceuticals: Product Portfolio

Table 43 Regeneron Pharmaceuticals: Key Developments

Table 44&nbsp; Amgen Inc: Overview

Table 45 Amgen Inc: Product Portfolio

Table 46&nbsp; Amgen Inc: Key Developments

Table 47 Daiichi Sankyo Company Limited: Overview

Table 48&nbsp; Daiichi Sankyo Company Limited: Product Portfolio

Table 49&nbsp; Daiichi Sankyo Company Limited: Key Developments

Table 50 Esperion Therapeutics: Overview

Table 51 Esperion Therapeutics: Product Portfolio

Table 52 Esperion Therapeutics: Key Developments

Table 53 Viatris Inc.: Overview

Table 54 Viatris Inc.: Product Portfolio

Table 55 Viatris Inc.: Key Developments

Table 56 Kowa Pharmaceuticals America, Inc.: Overview

Table 57 Kowa Pharmaceuticals America, Inc.: Product Portfolio

Table 58 Kowa Pharmaceuticals America, Inc.:Key Developments

Table 59 Merck &amp; Co., Inc.: Overview

Table 60&nbsp; Merck &amp; Co., Inc.:Product Portfolio

Table 61 Merck &amp; Co., Inc.:Key Developments

List of Figures

Figure 01 Global Familial Hypercholesterolemia Treatment Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 02 Global Familial Hypercholesterolemia Treatment Market Share, By Indication Type, 2022 &amp; 2030 (%)

Figure 03 Global Familial Hypercholesterolemia Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 04 Global Familial Hypercholesterolemia Treatment Market Share, By Region, 2022 &amp; 2030 (%)

Figure 05 Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 06 Global Familial Hypercholesterolemia Treatment Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 07 Drugs: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 08 Combination cholesterol absorption inhibitor and statin: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 09 Ezetimibe (Zetia): Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 10 PCSK9 inhibitors: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 11&nbsp; Fibrates: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 12&nbsp; Omega-3 fatty acid supplements: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 13&nbsp; Others: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 14 Global Familial Hypercholesterolemia Treatment Market Y-o-Y Growth, By Indication Type, 2022-2030 (%)

Figure 15&nbsp; Heterozygous familial hypercholesterolemia: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 16 Homozygous familial hypercholesterolemia: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 17&nbsp; Global Familial Hypercholesterolemia Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 18 Hospital Pharmacies: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 19 Retail Pharmacies: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 20 Other: Global Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 21&nbsp; Global Familial Hypercholesterolemia Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 23 North America Familial Hypercholesterolemia Treatment Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 24 North America Familial Hypercholesterolemia Treatment Market Share, By Indication Type, 2022 &amp; 2030 (%)

Figure 25 North America Familial Hypercholesterolemia Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 26 North America Familial Hypercholesterolemia Treatment Market Share, By Country, 2022 &amp; 2030 (%)

Figure 27 South America Familial Hypercholesterolemia Treatment Market Share, 2022-2030($ Million)

Figure 28 South America Familial Hypercholesterolemia Treatment Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 29 South America Familial Hypercholesterolemia Treatment Market Share, By Indication Type, 2022 &amp; 2030 (%)

Figure 30 South America Familial Hypercholesterolemia Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 31&nbsp; South America Familial Hypercholesterolemia Treatment Market Share, By Country, 2022 &amp; 2030 (%)

Figure 32 Europe Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 33 Europe Familial Hypercholesterolemia Treatment Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 34 Europe Familial Hypercholesterolemia Treatment Market Share, By Indication Type, 2022 &amp; 2030 (%)

Figure 35 Europe Familial Hypercholesterolemia Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 36 Europe Familial Hypercholesterolemia Treatment Market Share, By Country, 2022 &amp; 2030 (%)

Figure 37 Asia-Pacific Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 38 Asia-Pacific Familial Hypercholesterolemia Treatment Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 39 Asia-Pacific Familial Hypercholesterolemia Treatment Market Share, By Indication Type, 2022 &amp; 2030 (%)

Figure 40 Asia-Pacific Familial Hypercholesterolemia Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 41 Asia-Pacific Familial Hypercholesterolemia Treatment Market Share, By Country, 2022 &amp; 2030 (%)

Figure 42 Middle East &amp; Africa Familial Hypercholesterolemia Treatment Market Value, 2022-2030($ Million)

Figure 43 Middle East &amp; Africa Familial Hypercholesterolemia Treatment Market Share, By Drug Type, 2022 &amp; 2030 (%)

Figure 44 Middle East &amp; Africa Familial Hypercholesterolemia Treatment Market Share, By Indication Type, 2022 &amp; 2030 (%)

Figure 45 Middle East &amp; Africa Familial Hypercholesterolemia Treatment Market Share, By Distribution Channel, 2022 &amp; 2030 (%)

Figure 46 Novartis AG: Financials

Figure 47 Amryt Pharmaceuticals, Inc.: Financials

Figure 48 AstraZeneca Plc: Financials

Figure 49 Regeneron Pharmaceuticals: Financials

Figure 50 Amgen Inc: Financials

Figure 51&nbsp; Daiichi Sankyo Company Limited: Financials

Figure 52 Esperion Therapeutics: Financials

Figure 53 Viatris Inc.: Financials

Figure 54 Kowa Pharmaceuticals America, Inc.: Financials

Figure 55 Merck &amp; Co., Inc.: Financials

Familial Hypercholesterolemia Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Homozygous Familial Hypercholesterolemia Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Published: 2023 September 28

Starting from

Hyperparathyroidism Treatment Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Published: 2023 November 14

Starting from

Hyperuricemia Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Published: 2023 September 04

Starting from

Hypereosinophilic Syndrome Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 April 08

Starting from

Hyperthermia Devices Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 November 14

Starting from

Hypertrophic Cardiomyopathy Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 24

Starting from